How Regeneron’s COVID-19 Antibody Cocktail Cuts the Risk of Resistance

Source: FierceBiotech

When Regeneron said in March that it would speed an antibody treatment into clinical trials for COVID-19, its scientists insisted a cocktail of two antibodies would be more effective than one alone. Now they’re explaining why they chose the two antibodies that moved into human trials last week, according to a FierceBiotech report.

The reason, in short, was to thwart the ability of SARS-CoV-2, the virus at the heart of the pandemic, to mutate and cause patients to become resistant to treatment. The two antibodies Regeneron selected, REGN10933 and REGN10987, were less likely to generate “escape mutants” than individual antibodies or other cocktails the company’s scientists tested, they reported (PDF) in the journal Science.

Read the full article.

Related Content